Primary and secondary prevention of cardiovascular disease in older adults: a status report.
This article reviews cardiovascular disease (CVD) prevention in older patients, highlighting results from recent clinical studies related to primary and secondary prevention. Many of these studies demonstrated greater absolute reductions in major cardiovascular events among older, higher-risk populations compared with younger patients. Guideline recommendations for CVD risk factor modification are also reviewed with emphasis on issues pertaining to the older adult population.
Kriekard
Peter
P
Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. peter016@mc.duke.edu
Gharacholou
S Michael
SM
Peterson
Eric D
ED
D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003430:Cross-Sectional Studies; D005247:Feeding Behavior; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control; D006973:Hypertension / Q000209:etiology / Q000517:prevention & control; D008019:Life Style; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011157:Population Dynamics; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D016540:Smoking Cessation; D014481:United States
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors